首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Approved IFCC recommendation on reporting results for blood glucose: International Federation of Clinical Chemistry and Laboratory Medicine Scientific Division, Working Group on Selective Electrodes and Point-of-Care Testing (IFCC-SD-WG-SEPOCT).
【24h】

Approved IFCC recommendation on reporting results for blood glucose: International Federation of Clinical Chemistry and Laboratory Medicine Scientific Division, Working Group on Selective Electrodes and Point-of-Care Testing (IFCC-SD-WG-SEPOCT).

机译:IFCC已批准的有关报告血糖结果的建议:国际临床化学和实验室医学科学部联合会,选择性电极和即时护理测试工作组(IFCC-SD-WG-SEPOCT)。

获取原文
获取原文并翻译 | 示例
           

摘要

In current clinical practice, plasma and blood glucose are used interchangeably with a consequent risk of clinical misinterpretation. In human blood, glucose is distributed, like water, between erythrocytes and plasma. The molality of glucose (amount of glucose per unit water mass) is the same throughout the sample, but the concentration is higher in plasma, because the concentration of water and therefore glucose is higher in plasma than in erythrocytes. Different devices for the measurement of glucose may detect and report fundamentally different quantities. Different water concentrations in the calibrator, plasma, and erythrocyte fluid can explain some of the differences. Results for glucose measurements depend on the sample type and on whether the method requires sample dilution or uses biosensors in undiluted samples. If the results are mixed up or used indiscriminately, the differences may exceed the maximum allowable error for glucose determinations for diagnosing and monitoring diabetes mellitus, thus complicating patient treatment. The goal of the International Federation of Clinical Chemistry and Laboratory Medicine, Scientific Division, Working Group on Selective Electrodes and Point of Care Testing (IFCC-SD-WG-SEPOCT) is to reach a global consensus on reporting results. The document recommends reporting the concentration of glucose in plasma (in the unit mmol/L), irrespective of sample type or measurement technique. A constant factor of 1.11 is used to convert concentration in whole blood to the equivalent concentration in plasma. The conversion will provide harmonized results, facilitating the classification and care of patients and leading to fewer therapeutic misjudgments.
机译:在当前的临床实践中,血浆和血糖可互换使用,因此存在临床误解的风险。在人的血液中,葡萄糖像水一样在红细胞和血浆之间分布。葡萄糖的摩尔浓度(每单位水质量的葡萄糖量)在整个样品中都是相同的,但是血浆中的浓度较高,因为血浆中水的浓度因而葡萄糖比红细胞中的浓度高。用于测量葡萄糖的不同设备可能会检测并报告根本不同的数量。校准品,血浆和红细胞液中不同的水浓度可以解释某些差异。葡萄糖测量结果取决于样品类型以及该方法是否需要稀释样品或在未稀释样品中使用生物传感器。如果将结果混淆或不加区别地使用,则差异可能会超出用于诊断和监测糖尿病的葡萄糖测定的最大允许误差,从而使患者的治疗复杂化。国际临床化学和检验医学联合会科学部,选择性电极和即时护理测试工作组(IFCC-SD-WG-SEPOCT)的目标是就报告结果达成全球共识。该文件建议报告血浆中葡萄糖的浓度(单位mmol / L),与样品类型或测量技术无关。使用1.11的恒定因子将全血中的浓度转换为血浆中的等效浓度。转换将提供统一的结果,有利于对患者进行分类和护理,并减少对治疗的误判。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号